Myriad Genetics Inc
MYGN6.550USD
-0.010-0.15%
收盤 12/24, 13:00（美東）報價延遲15分鐘
609.80M總市值
虧損本益比TTM
關於 Myriad Genetics Inc 公司
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Myriad Genetics Inc簡介
公司代碼MYGN
公司名稱Myriad Genetics Inc
上市日期Oct 06, 1995
CEORaha (Samraat S)
員工數量2700
證券類型Ordinary Share
年結日Oct 06
公司地址322 North 2200 West
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編84116
電話18015843600
網址https://myriad.com/
公司代碼MYGN
上市日期Oct 06, 1995
CEORaha (Samraat S)
Myriad Genetics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
92.65K
-2.69%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
業務USD
名稱
營收
佔比
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
地區USD
名稱
營收
佔比
United States
198.20M
93.01%
Rest of world
14.90M
6.99%
業務
地區
業務USD
名稱
營收
佔比
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
股東統計
更新時間: 11月18日 週二
更新時間: 11月18日 週二
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.34%
State Street Investment Management (US)
5.34%
Millennium Management LLC
5.09%
Glenview Capital Management, LLC
4.92%
其他
62.09%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.34%
State Street Investment Management (US)
5.34%
Millennium Management LLC
5.09%
Glenview Capital Management, LLC
4.92%
其他
62.09%
股東類型
持股股東
佔比
Investment Advisor
37.68%
Investment Advisor/Hedge Fund
27.22%
Hedge Fund
25.48%
Research Firm
5.93%
Individual Investor
3.28%
Pension Fund
1.73%
Bank and Trust
0.41%
Family Office
0.24%
Sovereign Wealth Fund
0.04%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
518
92.00M
98.69%
-11.12M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
13.43M
14.43%
-416.99K
-3.01%
Jun 30, 2025
The Vanguard Group, Inc.
9.15M
9.83%
-1.47M
-13.83%
Jun 30, 2025
State Street Investment Management (US)
4.81M
5.17%
-458.84K
-8.71%
Jun 30, 2025
Millennium Management LLC
4.92M
5.29%
+855.19K
+21.01%
Jun 30, 2025
Glenview Capital Management, LLC
4.59M
4.93%
+687.86K
+17.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
4.51M
4.85%
+1.99M
+78.84%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
3.63%
+1.97M
+140.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.22M
2.39%
-7.80K
-0.35%
Jun 30, 2025
Camber Capital Management LP
2.00M
2.15%
-350.00K
-14.89%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Global X Genomics & Biotechnology ETF
0.8%
Invesco NASDAQ Future Gen 200 ETF
0.68%
Federated Hermes MDT Small Cap Core ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.46%
State Street SPDR S&P Biotech ETF
0.24%
Strategas Global Policy Opportunities ETF
0.22%
Inspire Small/Mid Cap ESG ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Quality Factor ETF
0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
查看更多
Global X Genomics & Biotechnology ETF
佔比0.8%
Invesco NASDAQ Future Gen 200 ETF
佔比0.68%
Federated Hermes MDT Small Cap Core ETF
佔比0.5%
Invesco S&P SmallCap Health Care ETF
佔比0.46%
State Street SPDR S&P Biotech ETF
佔比0.24%
Strategas Global Policy Opportunities ETF
佔比0.22%
Inspire Small/Mid Cap ESG ETF
佔比0.22%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.14%
Vanguard US Quality Factor ETF
佔比0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.12%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Myriad Genetics Inc的前五大股東是誰？
Myriad Genetics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.持有股份：13.43M佔總股份比例：14.43%。
The Vanguard Group, Inc.持有股份：9.15M佔總股份比例：9.83%。
State Street Investment Management (US)持有股份：4.81M佔總股份比例：5.17%。
Millennium Management LLC持有股份：4.92M佔總股份比例：5.29%。
Glenview Capital Management, LLC持有股份：4.59M佔總股份比例：4.93%。
BlackRock Institutional Trust Company, N.A.持有股份：13.43M佔總股份比例：14.43%。
The Vanguard Group, Inc.持有股份：9.15M佔總股份比例：9.83%。
State Street Investment Management (US)持有股份：4.81M佔總股份比例：5.17%。
Millennium Management LLC持有股份：4.92M佔總股份比例：5.29%。
Glenview Capital Management, LLC持有股份：4.59M佔總股份比例：4.93%。
Myriad Genetics Inc的前三大股東類型是什麼？
Myriad Genetics Inc 的前三大股東類型分別是：
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
有多少機構持有Myriad Genetics Inc(MYGN)的股份？
截至2025Q3，共有518家機構持有Myriad Genetics Inc的股份，合計持有的股份價值約為92.00M，占公司總股份的98.69% 。與2025Q2相比，機構持股有所增加，增幅為-9.65%。
哪個業務部門對Myriad Genetics Inc的收入貢獻最大？
在FY2025Q2，Hereditary Cancer業務部門對Myriad Genetics Inc的收入貢獻最大，創收96.30M，占總收入的45.19% 。
